TABLE 3.

Treatment and its Effect on Mortality in Different PRISM Score Categories

	PRISM Score <10 (n = 211)			PRISM Score 11-20 (n = 58)			PRISM Score >20 (n = 66)
	Survivors (n = 204)	Nonsurvivors (n = 7)	P value*	Survivors (n = 49)	Nonsurvivors (n = 9)	P value*	Survivors (n = 38)	Nonsurvivors (n = 28)	P value*
Favipiravir, n (%)	84 (41.2)	4 (57.1)	0.45	29 (59.2)	7 (77.8)	0.46	21 (55.3)	19 (67.9)	0.30**
Oseltamivir, n (%)	29 (14.2)	0 (0)	0.60	5 (10.2)	1 (11.1)	0.94	7 (18.4)	2 (7.1)	0.28
Lopinavir/ritonavir, n (%)	18 (8.8)	1 (14.3)	0.49	7 (14.3)	0 (0)	0.59	3 (7.9)	3 (10.7)	0.69
Remdesivir, n (%)	16 (7.8)	0 (0)	0.46	6 (12.2)	1 (11.1)	0.92	2 (5.4)	2 (7.1)	0.58
Hydroxychloroquine, n (%)	34 (16.7)	0 (0)	0.60	10 (20.4)	1(11.1)	0.51	10 (26.3)	6 (21.4)	0.65†
Glucocorticoid therapy, n (%)	83 (40.7)	3 (42.9)	0.91	28 (57.1)	7 (77.8)	0.30	23 (60.5)	18 (64.3)	0.76†
IVIG, n (%)	35 (19.5)	1 (14.3)	0.82	13 (26.5)	4 (44.4)	0.43	8 (21.1)	13 (46.4)	0.03 †
Convalescent plasma transfusion, n (%)	5 (2.5)	1 (14.3)	0.19	1 (2.0)	1 (11.1)	0.29	0 (0)	0 (0)	–
Anakinra, n (%)	2 (1.0)	0 (0)	0.79	0 (0)	0 (0)	–	1 (2.6)	0 (0)	0.58
Colchicine, n (%)	3 (1.5)	0 (0)	0.75	0 (0)	0 (0)	–	0 (0)	0 (0)	–
Tocilizumab, n (%)	1 (0.5)	0 (0)	0.85	0 (0)	0 (0)	–	1 (2.6)	0 (0)	0.58
Anticoagulation, n (%)	96 (47.1)	3 (42.9)	0.83	28 (57.1)	7 (77.8)	0.30	24 (63.2)	19 (67.9)	0.69†
Inotrope treatment, n (%)	14 (6.9)	6 (85.7)	0.00	12 (24.5)	9 (100)	0.00	16 (42.1)	27 (96.4)	0,00 †
Renal replacement therapy, n (%)	1 (0.6)	1 (14.3)	0.07	1 (2.0)	6 (66.7)	0.00	1 (2.6)	7 (25.0)	0.01
Plasma exchange, n (%)	7 (3.9)	0 (0)	0.62	5 (10.2)	4 (44.4)	0.03	2 (5.3)	4 (14.3)	0.39
Hemadsorption, n (%)	0 (0)	0 (0)	-	0 (0)	0 (0)	-	1 (2.6)	1 (3.6)	0.67
ECMO, n (%)	0 (0)	0 (0)	-	1 (2.0)	0 (0)	0.67	1 (2.6)	3 (10.7)	0.30

ECMO indicates extracorporeal membrane oxygenation; IVIG, intravenous immunoglobulin.

^*Fisher’s Exact Test.

^†Chi-Square test